Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 22, 2022 08:00 ET | Source: Noema Pharma

Noema Pharma announces first patient dosed in Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigeminal neuralgia

Study evaluating the efficacy of NOE-101 for management of pain associated with trigeminal neuralgia BASEL, Switzerland, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage...
February 14, 2022 08:00 ET | Source: Noema Pharma

Noema Pharma Announces FDA Investigational New Drug Authorization for Phase 2b LibraTN Study of mGluR5 Inhibitor NOE-101 in Trigeminal Neuralgia

Study to evaluate efficacy of NOE-101 for management of pain associated with trigeminal neuralgia BASEL, Switzerland, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage...
February 08, 2022 08:00 ET | Source: Noema Pharma

Noema Pharma to Host Key Opinion Leader Webinar on Trigeminal Neuralgia “Trigeminal Neuralgia? You are not alone”

Friday, February 11th 2012 - 12 pm EST / 6 pm CET Featuring Dr. Joanna Zakrzewska from University College London Hospital andTerence J. Coderre, Ph.D. from McGill University BASEL, Switzerland,...
December 08, 2021 02:00 ET | Source: Noema Pharma

Noema Pharma Hosting Key Opinion Leader Webinar on Stuttering

BASEL, Switzerland, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announced that it will host a...
November 09, 2021 08:55 ET | Source: Noema Pharma

Noema Pharma expands its Board of Directors with the appointments of Catherine Moukheibir and Ilise Lombardo

BASEL, Switzerland, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of...
October 04, 2021 02:00 ET | Source: Noema Pharma

Noema Pharma appoints Jeffrey Jonas as Independent Chairman of the Board of Directors

BASEL, Switzerland, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Noema Pharma AG, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of...
September 02, 2021 03:00 ET | Source: Noema Pharma

Noema Pharma to attend Swiss Biotech Day and the UBS Biotech Private Company Symposium in September 2021

BASEL, Switzerland, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces it will attend two...
August 05, 2021 01:30 ET | Source: Noema Pharma

Noema Pharma Initiates Phase 2a Allevia Study of PDE10A Inhibitor NOE-105 in Tourette Syndrome

First Noema clinical trial, with asset in-licensed from Roche with strong clinical safety packageNoema advancing potentially life-changing therapeutics for patients without satisfactory treatments ...
May 31, 2021 02:00 ET | Source: Noema Pharma

Noema Pharma to Attend Investor Conferences in June and July 2021

BASEL, Switzerland, May 31, 2021 (GLOBE NEWSWIRE) -- Noema Pharma (“Noema”) AG, a Swiss clinical-stage company targeting orphan neurological disorders, today announces it will attend several...
December 01, 2020 02:00 ET | Source: Noema Pharma

Noema Pharma raises CHF54 million in Series A financing round led by Sofinnova Partners and Polaris Partners

In-licensing of four clinical-stage product candidates to treat orphan neurological disordersHighly experienced team leverages latest scientific discoveries in neuroscienceFinancing will advance the...